OSE Immunotherapeutics - US patent to bolster Tedopi’s product portfolio
OSE Immunotherapeutics has announced that Tedopi, the company’s lead cancer vaccine candidate, has been granted a new patent by the United States...
445 Views
OSE Immunotherapeutics - New diagnostic test to support Tedopi trial
OSE Immunotherapeutics (OSE) has received €1.5m in non-dilutive funding from Bpifrance (a French public sector investment bank) to develop a...
180 Views
OSE Immunotherapeutics - Milestones anticipated throughout FY23
OSE Immunotherapeutics has announced its FY22 results, providing financial and operational updates as the company continues to advance its key...
250 Views
OSE Immunotherapeutics - Encouraging safety data for OSE-127
OSE Immunotherapeutics has announced that the data from its earlier Phase I study for OSE-127/S95011, initially released in 2019, has been...
266 Views
OSE Immunotherapeutics - FDA support received for Tedopi Phase III trial
OSE has announced that it has received positive recommendations from its ‘type C’ meeting with the FDA for the planned confirmatory Phase III trial...
517 Views